LAB STANDARD BIOTOOLS INC revenue, earnings and financials
For the quarter ended June 30, 2026, STANDARD BIOTOOLS INC reported revenue of $20.1M (down 7.6% from a year earlier), net income of −$26.8M and diluted EPS of −$0.07; over the last four quarters revenue was $84.6M and net income $84.9M; for the fiscal year ended December 2025 revenue was $85.3M, down 6.2% on the year before.
LAB annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $85.3M, gross profit $42.5M, operating income −$110M, net income −$74.9M (margin -87.8%), EPS −$0.20
- Fiscal year ended Dec 2024: revenue $91.0M, gross profit $44.9M, operating income −$127M, net income −$139M (margin -152.6%), EPS −$0.52
- Fiscal year ended Dec 2023: revenue $106M, gross profit $50.5M, operating income −$76.6M, net income −$74.7M (margin -70.2%), EPS −$0.94
- Fiscal year ended Dec 2022: revenue $97.9M, gross profit $37.1M, operating income −$116M, net income −$190M (margin -194.1%), EPS −$2.43
- Fiscal year ended Dec 2021: revenue $131M, gross profit n/a, operating income −$67.5M, net income −$59.2M (margin -45.4%), EPS −$0.78
LAB quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $20.1M (down 7.6% year over year), net income −$26.8M, EPS −$0.07
- Quarter ended Mar 31, 2026: revenue $21.1M (up 4.6% year over year), net income $127M, EPS $0.33
- Quarter ended Dec 31, 2025 (from the annual report): revenue $23.8M (up 2573.6% year over year), net income $19.3M, EPS $0.05
- Quarter ended Sep 30, 2025: revenue $19.6M (down 11.5% year over year), net income −$34.7M, EPS −$0.09
- Quarter ended Jun 30, 2025: revenue $21.8M (down 3.2% year over year), net income −$33.5M, EPS −$0.09
- Quarter ended Mar 31, 2025: revenue $20.2M (down 55.6% year over year), net income −$26.0M, EPS −$0.07
- Quarter ended Dec 31, 2024 (from the annual report): revenue $890K (down 96.8% year over year), net income −$34.1M, EPS −$0.06
- Quarter ended Sep 30, 2024: revenue $22.1M (down 12.9% year over year), net income −$26.9M, EPS −$0.07
- Quarter ended Jun 30, 2024: revenue $22.5M (down 18.7% year over year), net income −$45.7M, EPS −$0.12
- Quarter ended Mar 31, 2024: revenue $45.5M (up 81.3% year over year), net income −$32.2M, EPS −$0.27
- Quarter ended Dec 31, 2023 (from the annual report): revenue $28.2M (up 4.3% year over year), net income −$19.8M, EPS −$0.24
- Quarter ended Sep 30, 2023: revenue $25.4M (down 1.1% year over year), net income −$21.0M, EPS −$0.27
- Quarter ended Jun 30, 2023: revenue $27.7M (up 47.3% year over year), net income −$17.0M, EPS −$0.22
- Quarter ended Mar 31, 2023: revenue $25.1M (down 5.2% year over year), net income −$16.8M, EPS −$0.21
- Quarter ended Dec 31, 2022 (from the annual report): revenue $27.0M (down 29.4% year over year), net income −$20.8M, EPS −$0.25
- Quarter ended Sep 30, 2022: revenue $25.6M (down 10.0% year over year), net income −$29.4M, EPS −$0.37
- Quarter ended Jun 30, 2022: revenue $18.8M (down 39.5% year over year), net income −$63.5M, EPS −$0.82
- Quarter ended Mar 31, 2022: revenue $26.5M (down 19.2% year over year), net income −$76.3M, EPS −$0.99
- Quarter ended Dec 31, 2021 (from the annual report): revenue $38.3M, net income −$9.43M, EPS −$0.12
- Quarter ended Sep 30, 2021: revenue $28.5M, net income −$13.8M, EPS −$0.18
LAB cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$74.3M, share buybacks $0
- Fiscal year ended Dec 2024: operating cash flow −$143M, share buybacks $40.5M
- Fiscal year ended Dec 2023: operating cash flow −$43.3M, share buybacks $5.41M
- Fiscal year ended Dec 2022: operating cash flow −$89.4M, share buybacks $563K
- Fiscal year ended Dec 2021: operating cash flow −$44.1M, share buybacks $0
LAB balance sheet
- Jun 30, 2026: cash $270M, total assets $627M, total liabilities $87.2M, shareholders' equity $540M
- Mar 31, 2026: cash $266M, total assets $639M, total liabilities $78.0M, shareholders' equity $561M
- Dec 31, 2025: cash $121M, total assets $568M, total liabilities $143M, shareholders' equity $424M
- Sep 30, 2025: cash $129M, total assets $540M, total liabilities $140M, shareholders' equity $400M
- Jun 30, 2025: cash $159M, total assets $557M, total liabilities $132M, shareholders' equity $425M
- Mar 31, 2025: cash $151M, total assets $580M, total liabilities $125M, shareholders' equity $455M
- Dec 31, 2024: cash $167M, total assets $612M, total liabilities $141M, shareholders' equity $472M
- Sep 30, 2024: cash $211M, total assets $682M, total liabilities $192M, shareholders' equity $489M
What is LAB's revenue?
STANDARD BIOTOOLS INC reported $84.6M of revenue over its last four quarters, through June 30, 2026.
Is LAB profitable?
Yes. STANDARD BIOTOOLS INC earned $84.9M over the last four quarters.
What is LAB's EPS?
Diluted earnings per share over the last four quarters were $0.22; −$0.07 in the latest quarter.